Status:
COMPLETED
Is Anti-Factor Xa Associated With Outcome in Patients With Critical COVID-19 on Low-Molecular-Weight Heparin?
Lead Sponsor:
Karolinska Institutet
Collaborating Sponsors:
Lund University
Conditions:
Covid19
Thromboembolism
Eligibility:
All Genders
18+ years
Brief Summary
Patients with critical COVID-19 are hyper-coagulable and optimal thromboprophylaxis treatment differs with stage and severity. The most commonly used drug for thromboprophylaxis in the intensive care ...
Eligibility Criteria
Inclusion
- Patients with critical COVID-19 and respiratory failure
- Positive SARS-CoV-2 test
- LMWH-effect monitored by aFXa, as a trough or peak value, after at least four doses at a twice daily regime
Exclusion
- Diagnosed thromboembolism or major bleeding during their COVID-illness prior to ICU-admission or as a reason or contributing factor for the ICU-admission.
- Transferred to or from an ICU in other hospital/region making data collection regarding baseline data/outcomes not possible
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 29 2021
Estimated Enrollment :
1520 Patients enrolled
Trial Details
Trial ID
NCT05256524
Start Date
March 1 2020
End Date
August 29 2021
Last Update
February 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Södersjukhuset
Stockholm, Sweden, 11883